Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $633.1 million.

  • Amicus Therapeutics' Total Non-Current Liabilities rose 6.53% to $633.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.1 million, marking a year-over-year increase of 6.53%. This contributed to the annual value of $583.9 million for FY2024, which is 3.40% down from last year.
  • Per Amicus Therapeutics' latest filing, its Total Non-Current Liabilities stood at $633.1 million for Q3 2025, which was up 5.10% from $602.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Total Non-Current Liabilities ranged from a high of $633.1 million in Q3 2025 and a low of $532.8 million during Q1 2021.
  • In the last 3 years, Amicus Therapeutics' Total Non-Current Liabilities had a median value of $602.4 million in 2025 and averaged $600.1 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 72.59% in 2021, then dropped by 4.44% in 2024.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Total Non-Current Liabilities stood at $577.4 million in 2021, then rose by 0.39% to $579.7 million in 2022, then increased by 4.26% to $604.4 million in 2023, then dropped by 3.40% to $583.9 million in 2024, then grew by 6.53% to $633.1 million in 2025.
  • Its Total Non-Current Liabilities was $633.1 million in Q3 2025, compared to $602.4 million in Q2 2025 and $587.8 million in Q1 2025.